Stock Ratings / Health Care / DMAC / earnings

INDP (36) ARVN (37) OCS (58) AQST (27) ⌘ Pro Terminal →

DiaMedica Therapeutics Inc. (DMAC) Next Earnings Date & Expected ±12.5% Move

$9.52 -3.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.45

DiaMedica Therapeutics Inc. (DMAC) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $513.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.45 (-0.74%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DMAC)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY DMAC SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 83% of 52W Range • RSI-14 at 63 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$8.33-9.1% Next Q

Q2 (-2Q)

Grade E$7.57+15.2% Next Q

Q3 (-1Q)

Grade E$8.72+9.2% Next Q

Current

Grade E$9.52-8.7% Hist 90D α

Trajectory: E (26) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DMAC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DMAC currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.61) and Max Pain ($10.00) forces dealer call-delta covering toward $10.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DMAC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DMAC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.19 Expected Swing

MODEL EARNINGS SETUP GAUGE

DMAC Quantitative Pre-Earnings Setup: 34/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (34/100)Model Risk Weight (66/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$32.8M	-$29.1M	52%
FY 2024	2024-12-31	$0	-$24.4M	-$22.1M	52%
FY 2023	2023-12-31	$0	-$19.4M	-$18.7M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DMAC)

✓Walkthrough of DMAC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DMAC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +57.36%▲ ASCENDING CHANNEL

2026-10-30O $9.39H $9.54L $9.12C $9.52VOL 174.6K

RES: $10.17SUP: $6.99SMA50: $7.61SMA200: $7.11

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DMAC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DMAC Butterfly Map → + Track DMAC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DMAC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DMAC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DMAC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DMAC)

Health Care Rank #839 of 1016 ⚔️ INDP vs DMAC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DMAC vs. INDP, ARVN, OCS, AQST)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, DiaMedica Therapeutics Inc. (DMAC) ranks #839 by composite RQD confidence (34/100, grade E) and #445 by equity capitalization ($513.4M). Within this direct 5-issuer industry benchmark cohort, DMAC leads on earnings valuation at N/A trailing P/E, while ARVN leads on capital efficiency and profitability with -32.1% ROIC and — gross margin. OCS currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with DMAC at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DMAC ACTIVE DiaMedica Therapeutics Inc.	E	34/100	—	—	-35.0%	-3.05%	$513.4M	Benchmark Subject
INDP Indaptus Therapeutics Inc.	D-	36/100	—	—	-35.0%	+0.30%	$513.0M	/indp-vs-dmac →
ARVN Arvinas Inc.	D-	37/100	—	—	-32.1%	+3.95%	$516.6M	/arvn-vs-dmac →
OCS Oculis Holding AG	D+	58/100	—	—	—	+3.26%	$507.5M	/ocs-vs-dmac →
AQST Aquestive Therapeutics Inc.	E	27/100	—	58.3%	-35.0%	-4.49%	$507.1M	/aqst-vs-dmac →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001401040

In its most recent audited fiscal period (FY2025, filed 2025-12-31), DiaMedica Therapeutics Inc. (DMAC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$32.8M, operating cash flow of -$29.1M, and free cash flow of -$29.1M (-31.7% YoY). On the balance sheet, DMAC closed FY2025 with $61.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$32.8M	-$29.1M	-$29.1M	$61.4M	—
FY2024 (FY)	2024-12-31	$0	-$24.4M	-$22.1M	-$22.1M	$46.3M	—
FY2023 (FY)	2023-12-31	$0	-$19.4M	-$18.7M	-$18.7M	—	—

3. DMAC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DMAC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $9.52 (-3.05% 1D, market cap $513.4M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DMAC ranks #839 in composite RQD confidence.

How does DMAC compare to INDP and ARVN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DMAC carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INDP (Indaptus Therapeutics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $513.0M) and ARVN (Arvinas Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -32.1%, cap $516.6M). Among the 5-stock peer group, DMAC leads on earnings multiple (N/A) while ARVN leads on capital efficiency (-32.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DMAC?

Per DMAC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001401040), DiaMedica Therapeutics Inc. generated $0 in revenue, -$32.8M in net income, and -$29.1M in free cash flow against $61.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DMAC trading relative to its 50-day, 200-day, and 52-week technical levels?

DMAC last traded at $9.52 (-3.05% on volume of 196,521 shares), positioning the stock +25.10% above its 50-day simple moving average ($7.61) and +33.90% above its 200-day simple moving average ($7.11). Across its 52-week range of $5.25 to $10.42, DMAC sits at the 82.6% percentile with a 14-day RSI of 63.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($8.33 to $10.71).

DMAC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is DMAC's next earnings date?

Based on SEC filing cadence, DiaMedica Therapeutics Inc. (DMAC)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is DMAC stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for DMAC, spanning a range between $8.33 and $10.71.

Direct Sub-Reports: DMAC RQD Cockpit DMAC 12M Forecast DMAC Earnings & Move DMAC Dividends & DRIP DMAC Insiders & 13F DMAC Whale Options DMAC Profit Sankey DMAC News & Why